Sarah K. Browne, M.D., Vice President, Clinical Development obtained her medical degree at Virginia Commonwealth University, Richmond, VA, trained in Internal Medicine at Brigham and Women’s Hospital, Boston, MA, and completed a Clinical and Infectious Diseases Fellowship at the National Institute of Allergy and Infectious diseases, National Institutes of Health (NIAID, NIH). After Fellowship, Dr. Browne remained at NIAID as an Assistant Clinical Investigator. Her research focused on characterizing the clinical and scientific features of an emerging group of adult-onset immunodeficiencies related to endogenously produced high-titer, neutralizing, anticytokine autoantibodies. Subsequently, she joined the US Food and Drug Administration (FDA) in the Division of Vaccines and Related Product Applications, Office of Vaccines Research and Review (OVRR), part of the Center for Biologics Evaluation and Research (CBER). Initially, she served as a clinical reviewer on numerous original and supplemental Biologics License Applications and Investigational New Drug applications, and subsequently transitioned to Senior Advisor for Clinical Review where she engaged in management review and policy decisions pertaining to products regulated by OVRR. In October 2020, she joined Altimmune, and currently serves as the functional lead for the pemvidutide and HepTcell clinical development programs. She maintains a clinical practice in infectious diseases as a volunteer at the Veterans Affairs Medical Center Hospital located in Washington, DC.
